<?xml version="1.0" encoding="iso-8859-1"?> 
<rss version="2.0" xmlns:creativeCommons="http://backend.userland.com/creativeCommonsRssModule" 
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" 
xmlns:atom="http://www.w3.org/2005/Atom"
>
<channel>
<title>International Journal of Medical Sciences</title> 
<link>http://www.medsci.org</link> 
<description>International Journal of Medical Sciences RSS feed -- Volume 5</description> 
<language>en-us</language> 
<pubDate>Tue, 20 Nov 2012 04:00:00 GMT</pubDate>
<lastBuildDate>Tue, 20 Nov 2012 04:00:00 GMT</lastBuildDate> 


<item>
<link>http://www.medsci.org/v05p0371.htm</link> 
<title>Inhalation with Fucose and Galactose for Treatment of Pseudomonas Aeruginosa in Cystic Fibrosis Patients</title> 
<description><![CDATA[ <p>Background: Colonisation of cystic fibrosis (CF) lungs with <i>Pseudomonas aeruginosa</i> is facilitated by two lectins, which bind to the sugar coat of the surface lining epithelia and stop the cilia beating.</p> <p>Objectives: We hypothesized that <i>P. aeruginosa</i> lung infection should be cleared by inhalation of fucose and galactose, which compete for the sugar binding site of the two lectins and thus inhibit the binding of <i>P. aeruginosa.</i></p> <p>Methods: 11 adult CF patients with chronic infection with <i>P. aeruginosa</i> were treated twice daily with inhalation of a fucose/galactose solution for 21 days (4 patients only received inhalation, 7 patients received inhalation and intravenous antibiotics). Microbial counts of <i>P. aeruginosa</i>, lung function measurements, and inflammatory markers were determined before and after treatment.</p> <p>Results: The sugar inhalation was well tolerated and no adverse side effects were observed. Inhalation alone as well as combined therapy (inhalation and antibiotics) significantly decreased <i>P. aeruginosa</i> in sputum (P &#60; 0.05). Both therapies also significantly reduced TNF&#945; expression in sputum and peripheral blood cells (P &#60; 0.05). No change in lung function measurements was observed.</p> <p>Conclusions: Inhalation of simple sugars is a safe and effective measure to reduce the <i>P. aeruginosa</i> counts in CF patients. This may provide an alternative therapeutical approach to treat infection with <i>P. aeruginosa</i>.</p> ]]></description>  
<dc:creator>Hans-Peter Hauber, Maria Schulz, Almuth Pforte, Dietrich Mack, Peter Zabel, Udo Schumacher</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>371</prism:startingPage> 
<prism:endingPage>376</prism:endingPage> 
<pubDate>2008-11-17</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0366.htm</link> 
<title>Hypoalbuminaemia &#8211; A Marker of Cardiovascular Disease in Patients with Chronic Kidney Disease Stages II - IV</title> 
<description><![CDATA[ <p>Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD) patients. Serum albumin, a negative acute-phase reactant and marker for underlying inflammation and/or malnutrition, is an independent predictor of CVD and mortality in CKD VI patients. Such an association in patients with less severe CKD is not well established.</p> <p>We conducted a cross sectional study of all CKD II - IV patients attending the nephrology clinic (N=376; mean age: 57&#177;17 years; GFR: 47&#177;20 mL/min/1.73m2; females 48%; blacks 15%; diabetics 27%; hypertensive 79%). Laboratory and clinical data including risk factors and evidence of CVD were obtained at the point of the most recent visit. The association between risk factors and CVD was evaluated by logistic regression. In the simple logistic regression model, age (p&#60;0.0001), sex (P= 0.02), hypertension (P&#60;0.0001), diabetes (P&#60;.0001), dyslipidemia (p=.01), and serum albumin (p&#60;.0001) were found to be statistically significant. Serum albumin was found to be an independent predictor (p=0.04) of CVD by multiple logistic regression analysis using the above risk factor variables.</p> <p>In conclusion: a) hypoalbuminaemia is an independent predictor of CVD in early CKD stages; b) hypoalbuminaemia may be used to identify the population at higher risk for CVD.</p> ]]></description>  
<dc:creator>Nehal Rachit Shah, Francis Dumler</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>366</prism:startingPage> 
<prism:endingPage>370</prism:endingPage> 
<pubDate>2008-11-12</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0361.htm</link> 
<title>Allele dependent silencing of COL1A2 using small interfering RNAs</title> 
<description><![CDATA[ <p>Osteogenesis imperfecta (OI) is generally caused by a dominant mutation in Collagen I, encoded by the genes <i>COL1A1</i> and<i> COL1A2</i>. To date there is no satisfactory therapy for OI, but inactivation of the mutant allele through small interfering RNAs (siRNA) is a promising approach, as siRNAs targeting each allele of a polymorphism could be used for allele-specific silencing irrespective of the location of the actual mutations. In this study we examined the allele dependent effects of several tiled siRNAs targeting a region surrounding an exonic <i>COL1A2 </i>T/C polymorphism (rs1800222) in heterozygous primary human bone cells. Relative abundances of <i>COL1A2</i> alleles were determined by cDNA sequencing and overall <i>COL1A2</i> abundance was analyzed by quantitative PCR. One of the siRNAs decreased overall <i>COL1A2</i> abundance by 71% of which 75% was due to silencing of the targeted T-allele. In conclusion, allele-preferential silencing of Collagen type I genes may be a future therapeutic approach for OI.</p> ]]></description>  
<dc:creator>Katarina Lindahl, Carl-Johan Rubin, Andreas Kindmark, &#214;sten Ljunggren</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>361</prism:startingPage> 
<prism:endingPage>365</prism:endingPage> 
<pubDate>2008-11-12</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0354.htm</link> 
<title>An innovative method to evaluate the suture compliance in sealing the surgical wound lips</title> 
<description><![CDATA[ <p><b>Background and aim: </b>The increasing number of surgical procedures performed with local anesthesia, followed by immediate patient discharge from the hospital, emphasizes the need for a tight waterproof suture that is capable of maintaining its tensile strength in the postoperative phase when the wound tumescence, edema due to the anesthetic drug, and surgical trauma disappear. Moreover, the issue of having an accurate surgical wound closure is very relevant <i>in vivo</i> in order to prevent hemorrhage and exogenous microbial infections. This study aimed at designing a new a lab technique that could be used for evaluating the best surgical material. Using such a technique, we compared the wound-lip-sealing properties of three commonly-used suture threads, namely polyurethane, polypropylene, and polyamide.</p> <p><b>Materials and methods:</b> The mechanical properties of same-size suture threads made from polyurethane, polypropylene, and polyamide, were compared in order to define the one that possess the best elastic properties by being able to counteract the tension-relaxation process in the first 12 hours following surgery. The tension holding capacity of the suture materials was measured in both <i>in vivo</i> and <i>in vitro</i> experiments. The surface area of the scar associated with the three different suture threads was measured and compared, and the permeability of the three different suture threads was assessed at 0 minute, 2 minute, 4 minute, 6 minute, and 8 minute- interval.</p> <p><b>Results: </b>Results showed that polyurethane suture threads had significantly (P &#60; 0.05) better tensile strength, elongation endurance before breakage, and better elasticity coefficient as compared to polypropylene and polyamide suture threads. Moreover, polyurethane suture threads were significantly (P &#60; 0.05) more impermeable as compared to the other two suture thread types (polypropylene and polyamide). This impermeability was also associated with a tighter wound-lip-sealing ability, and with significantly (P &#60; 0.05) less scar formation.</p> <p><b>Conclusion: </b> Among the main concerns that surgeons, physicians, and patients often have is the development infection, oozing, and scar at the incision site following suturing. This always raises the question about which suture to use to avoid the above problems. This study provides evidence that the new technique developed in our lab could be used to compare the wound-lip sealing properties of different surgical suture threads. Using such a technique, the results show that polyurethane is significantly better than other commonly-used suture threads, like polypropylene and polyamide, in relation to wound sealing and scar formation.</p> ]]></description>  
<dc:creator>Farid Saleh, Beniamino Palmieri, Danielle Lodi, Khalid Al-Sebeih</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>354</prism:startingPage> 
<prism:endingPage>360</prism:endingPage> 
<pubDate>2008-11-11</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0347.htm</link> 
<title>Prion propagation in vitro: are we there yet?</title> 
<description><![CDATA[ <p>Prion diseases are caused by proteinaceous pathogens termed prions. Although the details of the mechanism of prion propagation are not fully understood, conformational conversion of cellular prion protein (PrP<sup>C</sup>) to misfolded, disease-associated scrapie prion protein (PrP<sup>Sc</sup>) is considered the essential biochemical event for prion replication. Currently, studying prion replication <i>in vitro</i> is difficult due to the lack of a system which fully recapitulates the <i>in vivo</i> phenomenon. Over the last 15 years, a number of <i>in vitro</i> systems supporting PrP<sup>C</sup> conversion, PrP<sup>Sc</sup> amplification, or amyloid fibril formation have been established. In this review, we describe the evolving methodology of <i>in vitro</i> prion propagation assays and discuss their ability in reflecting prion propagation<i> in vivo</i>.</p> ]]></description>  
<dc:creator>Chongsuk Ryou, Charles E. Mays</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>347</prism:startingPage> 
<prism:endingPage>353</prism:endingPage> 
<pubDate>2008-11-11</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0341.htm</link> 
<title>XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer</title> 
<description><![CDATA[ <p>Combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated. Such combinations potentially would provide a promising non&#8211;anthracycline-based alternative for patients with early breast cancer. Non-anthracycline preoperative regimens are a particularly interesting proposition in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, as they offer less cardiotoxicity and thus can be used concomitantly with preoperative trastuzumab therapy. Capecitabine plus docetaxel (XT) and trastuzumab with XT (HXT) are promising non-anthracycline regimens for the preoperative treatment of women with HER2-negative and HER2-positive breast cancer, respectively. The Xeloda in Neoadjuvant (XeNA) trial, an open-label, multicenter, phase II study, independently assesses the efficacy of preoperative XT in HER2-negative and HXT in HER2-positive breast cancer. A particularly important feature of the XeNA study is the use of pathologic complete response (pCR) plus near pCR (npCR) as the primary endpoint. pCR is associated with long-term survival, and although it is valuable as a surrogate marker, pCR has some limitations. Measurement of residual breast cancer burden (RCB) has been proposed as a more practical alternative to predict survival after preoperative chemotherapy. The combination of RCB-0 and RCB-I (npCR) expands the subset of patients shown to benefit from preoperative chemotherapy, and achievement of pCR or npCR is associated with long disease-free survival. In XeNA, the sum of pCR and npCR will facilitate correlative studies designed to identify patients most likely to benefit from XT and HXT and may expedite the clinical evaluation of these novel preoperative regimens.</p> ]]></description>  
<dc:creator>Stefan Gl&#252;ck, Edward F. McKenna Jr, Melanie Royce</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>341</prism:startingPage> 
<prism:endingPage>346</prism:endingPage> 
<pubDate>2008-11-4</pubDate>
<category>Short Research Communication</category>
</item>

<item>
<link>http://www.medsci.org/v05p0333.htm</link> 
<title>Different effect of exercise on left ventricular diastolic time and interventricular dyssynchrony in heart failure patients with and without left bundle branch block</title> 
<description><![CDATA[ <p>Background: In patients with idiopathic dilated cardiomyopathy (IDCM) a prolongation of left ventricular (LV) systole at the expense of diastolic time was demonstrated. Our study was aimed to evaluate the effect of exercise on heart rate corrected diastolic time in controls, IDCM with and without LBBB, and patients with LBBB and normal LV function.</p> <p>Methods: 47 patients with IDCM, 30 without LBBB, and 17 with LBBB as well as 11 with isolated LBBB were studied during exercise using a combined hemodynamic-radionuclide angiographic approach. The phases of the cardiac cycle were derived with high temporal resolution from the ventricular time-activity curve. The loss of diastolic time per beat (LDT) was quantified using a regression equation obtained from a control group (n=24).</p> <p>Results: A significant LDT was demonstrated at rest and during peak exercise in IDCM patients with LBBB (39.1&#177;32 and 37.3&#177;30 ms; p &#60; 0.001). In IDCM patients with normal activation LDT was unaffected at baseline, but elevated during peak exercise. This response was paralleled by an increase in interventricular mechanical dyssynchrony.</p> <p>Conclusion: During exercise an abnormal shortening of LV diastolic time is a common characteristic of heart failure patients which can be explained by the high prevalence of mechanical dyssynchrony.</p> ]]></description>  
<dc:creator>Gunnar Plehn, Julia Vormbrock, Thomas Butz, Martin Christ, Hans-Joachim Trappe, Axel Meissner</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>333</prism:startingPage> 
<prism:endingPage>340</prism:endingPage> 
<pubDate>2008-11-4</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0327.htm</link> 
<title>Efficacy of Radiofrequency Ablation of Hepatocellular Carcinoma Associated with Chronic Liver Disease without Cirrhosis</title> 
<description><![CDATA[ <p>Background. Hepatocellular carcinoma is one of the leading causes of death for compensated chronic liver disease.</p> <p>Aim. The evaluation of technical success as primary ablation rate, local tumor progression, safety, and long&#173;-term patients outcome of radiofrequency ablation in single (less than 3.5 cm in diameter) or multiple nodules (up to 3, sized less than 3 cm) of hepatocellular carcinoma associated to chronic liver disease without cirrhosis.</p> <p>Materials and Methods. 25 consecutive patients, mainly chronic hepatitis C, with surgical unresectable hepatocellular carcinoma due to comorbidity or tumor location recruited from a local sonographic screening, were treated.</p> <p>Results. Primary ablation was obtained in 96% of patients (24 out of 25) and in 93 % of nodules (27 out of 29). 1, 3, and 5-year local tumor progression rates after treatment were 4, 14, and 14%. Survival rates at 1,3, and 5-year were 92, 72, and 64%. No treatment-related deaths and severe complications were recorded.</p> <p>Conclusions. Radiofrequency ablation is effective with 96% of primary ablation with few tumoral recurrence and limited morbidity in patients with hepatocellular carcinoma associated with chronic liver disease without cirrhosis, it could represent a valid alternative treatment whenever surgical therapy is not safe.</p> ]]></description>  
<dc:creator>Andrea Salmi, Renato Turrini, Giovanna Lanzani, Antonella Savio, Livio Anglani</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>327</prism:startingPage> 
<prism:endingPage>332</prism:endingPage> 
<pubDate>2008-10-27</pubDate>
<category>Short Research Communication</category>
</item>

<item>
<link>http://www.medsci.org/v05p0319.htm</link> 
<title>Controlling Osteogenesis and Adipogenesis of Mesenchymal Stromal Cells by Regulating A Circadian Clock Protein with Laser Irradiation</title> 
<description><![CDATA[ <p>Mesenchymal stromal cells (MSCs) are multipotent cells present in adult bone marrow that replicate as undifferentiated cells and can differentiate to lineages of mesenchymal tissues. Homeostatic control of bone remodelling maintains bone mass by insuring that bone resorption and bone formation occur sequentially and in a balanced manner. As most homeostatic functions occur in a circadian manner, a circadian clock could control bone mass. Here, we show that laser irradiation can direct the osteogenesis and adipogenesis of mouse MSCs by altering the intracellular localization of the circadian rhythm protein Cryptochrome 1 (mCRY1). After laser irradiation (wavelength: 405 nm) to MSCs, circadian rhythm protein, mCRY1 and mPER2, were immunostained and histochemical stainings for osteogenic or adipogenic differentiation were observed. Laser irradiation promoted osteogenesis and reduced adipogenesis of MSCs, induced the translocation of mCRY1 and mPER2 protein from the cytoplasm to the nucleus, and decreased mCRY1 mRNA levels quantified by real-time PCR. Since the timing of nuclear accumulation of clock proteins constitutes an important step in the transcription-translation feedback loop driving the circadian core oscillator, laser irradiation could provide a simple and effective technology for clock protein localization and turnover. Our results also indicate that mCRY1 is a master regulator of circadian rhythm that regulates the differentiation of MSCs. Laser irradiation could provide a simple and effective means of controlling the fate of MSCs as a therapeutic strategy and act 'molecular switch' of regulatory proteins by suppressing CRY transcription. Furthermore, this model system may be useful for exploring the crosstalk between circadian rhythm and cell differentiation.</p> ]]></description>  
<dc:creator>Toshihiro Kushibiki, Kunio Awazu</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>319</prism:startingPage> 
<prism:endingPage>326</prism:endingPage> 
<pubDate>2008-10-26</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0313.htm</link> 
<title>The treatment of condylar fractures: to open or not to open? A critical review of this controversy</title> 
<description><![CDATA[ <p>The treatment of condylar process fractures has generated a great deal of discussion and controversy in oral and maxillofacial trauma and there are many different methods to treat this injury. For each type of condylar fracture, the techniques must be chosen taking into consideration the presence of teeth, fracture height, patient's adaptation, patient's masticatory system, disturbance of occlusal function, deviation of the mandible, internal derangements of the temporomandibular Joint (TMJ) and ankylosis of the joint with resultant inability to move the jaw, all of which are sequelae of this injury. Many surgeons seem to favor closed treatment with maxillomandibular fixation (MMF), but in recent years, open treatment of condylar fractures with rigid internal fixation (RIF) has become more common. The objective of this review was to evaluate the main variables that determine the choice of method for treatment of condylar fractures: open or closed, pointing out their indications, contra-indications, advantages and disadvantages.</p> ]]></description>  
<dc:creator>Renato VALIATI, Danilo IBRAHIM, Marcelo Emir Requia ABREU, Claiton HEITZ, Rog&#233;rio Belle de OLIVEIRA, Rog&#233;rio Miranda PAGNONCELLI, Daniela Nascimento SILVA</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>313</prism:startingPage> 
<prism:endingPage>318</prism:endingPage> 
<pubDate>2008-10-23</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0309.htm</link> 
<title>Lamivudine treatment for severe acute HBV hepatitis</title> 
<description><![CDATA[ <p>Treatment for acute hepatitis B is recommended in order to reduce the risk of progression to fulminant hepatitis and the need of OLT. We report our experience on treatment with high dose lamivudine, in patients with severe acute HBV infection. The diagnosis was based on clinical and virological findings and exclusion of other known causes of liver damage. The decision to treat was based on the prolongation of INR together with increasing values of bilirubin and ALT. Four patients received Lamivudine 200 mg/daily until clearance of serum HBV-DNA and then 100 mg/daily until clearance of HBsAg and appearance of anti-HBs antibodies. One patient received 100 mg/daily because of chronic renal impairment. The median period of hospitalization was 13 days, and none of the patients had complications, related either to underlying disease or to therapy. The complete normalization of serum transaminases and bilirubin occurred on average after 5.5 weeks and 3 weeks respectively. All patients cleared serum HBV-DNA within three months, lost HBeAg and HBsAg and seroconverted to anti-HBe; four patients developed anti-HBs at a protective titre. Early antiviral treatment attenuates the clinical and biochemical impairment leading to fast healing and promoting complete recovery.</p> ]]></description>  
<dc:creator>Andrea Lisotti, Francesco Azzaroli, Federica Buonfiglioli, Marco Montagnani, Flavio Alessandrelli, Giuseppe Mazzella</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>309</prism:startingPage> 
<prism:endingPage>312</prism:endingPage> 
<pubDate>2008-10-23</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0303.htm</link> 
<title>Enhanced Diagnostic Yield with Prolonged Small Bowel Transit Time during Capsule Endoscopy</title> 
<description><![CDATA[ <p><b>Background: </b>The effect of small bowel transit time (SBTT) on diagnostic yield during capsule endoscopy (CE) has not been previously evaluated. Our study aim was to assess the effect of SBTT on the likelihood of detecting intestinal pathology during CE. <b>Methods: </b>We reviewed collected data on CE studies performed at Johns Hopkins Hospital from January 2006 to June 2007. In patients investigated for anemia or obscure bleeding, the following lesions were considered relevant: ulcers, erosions, AVMs, red spots, varices, vascular ectasias, and presence of blood. In patients with diarrhea or abdominal pain, ulcers, erosions, and blood were considered relevant. Age, gender, study indication, hospital status, and quality of bowel preparation were identified as candidate risk factors affecting SBTT. Univariate logistic and linear regression analyses were performed to study the effect of SBTT on diagnostic yield. <b>Results: </b>Total of 212 CE studies were analyzed; most were in outpatients (n=175, 82.9%) and with excellent bowel preparation (n=177, 83.5%). Mean SBTT was 237.0min (3.9hrs). Age, gender, bowel prep, hospital status, and study indication did not significantly affect SBTT. However, increased SBTT was independently associated with increased diagnostic yield; OR=1.7 in SBTT=2-4hr (p=0.41), OR=1.8 in SBTT=4-6hrs (p=0.30), OR=9.6 in SBTT=6-8hrs (p=0.05). <b>Conclusion:</b> Prolonged SBTT during CE (&#62;6 hr) is associated with an increased diagnostic yield. This may be due to a positive effect on image quality during a &#8220;slower&#8221; study. The use of promotility agents may adversely affect the ability of CE to detect significant intestinal pathology.</p> ]]></description>  
<dc:creator>Jonathan M. Buscaglia, Sumit Kapoor, John O. Clarke, Juan Carlos Bucobo, Samuel A. Giday, Priscilla Magno, Elaine Yong, Gerard E. Mullin</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>303</prism:startingPage> 
<prism:endingPage>308</prism:endingPage> 
<pubDate>2008-10-22</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0295.htm</link> 
<title>Upregulation of Bax and Bcl-2 following prenatal cocaine exposure induces apoptosis in fetal rat brain</title> 
<description><![CDATA[ <p>Cocaine abuse during pregnancy has been associated with numerous adverse perinatal outcomes. <b>Aims: </b>The present study was to determine whether prenatal cocaine exposure induced apoptosis and the possible role of Bcl-2 family genes in the programming cell death in fetal rat brain. <b>Main methods:</b> Pregnant rats were treated with cocaine subcutaneously (30 &#38; 60 mg/kg/day) from day 15 to 21 of gestation. Then the fetal and maternal brains were isolated. <b>Key findings:</b> Cocaine produced a dose-dependent decrease in fetal brain weight and brain/body weight ratio (P&#60;0.05). Apoptotic nuclei in fetal brain were increased from 2.6 &#177; 0.1 (control) to 8.1&#177; 0.6 (low dose) and 10.4 &#177; 0.2% (high dose) (P&#60;0.05). In accordance, cocaine dose dependently increased activities of caspase-3, caspase-8, and caspase-9 (% of control) in the fetal brain by 177%, 155%, 174%, respectively, at 30 mg/kg/day, and by 191%, 176%, 274%, respectively, at 60 mg/kg/day. In contrast, cocaine showed no effect on caspase activities in the maternal brain. Cocaine produced a dose-dependent increase in both Bcl-2 and Bax protein expression in the fetal brain, and increased the ratio of Bax/Bcl-2 at dose of 30 mg/kg/day (P&#60;0.05). <b>Significance: </b>Our study has demonstrated that prenatal cocaine exposure induces apoptosis in the fetal brain, and suggested that up-regulating Bax/Bcl-2 gene expression may be involved in cocaine-induced apoptosis. The increased apoptosis of neuronal cells in the fetal brain is likely to play a key role in cocaine-induced neuronal defects during fetal development.</p> ]]></description>  
<dc:creator>DaLiao Xiao, Lubo Zhang</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>6</prism:number> 
<prism:startingPage>295</prism:startingPage> 
<prism:endingPage>302</prism:endingPage> 
<pubDate>2008-10-17</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0292.htm</link> 
<title>Simultaneous dislocation of the radial head and distal radio-ulnar joint. A case report</title> 
<description><![CDATA[ <p>Isolated dislocation of the distal radio-ulnar joint and isolated dislocation of the radial head in adults are not common injuries. A simultaneous dislocation of the radial head and distal radio-ulnar joint with no other injury seems to be extremely rare since only one report was found in the English literature. A similar case, but with some differences in presentation and treatment is reported.</p> ]]></description>  
<dc:creator>D-A.J. Verettas, G.I. Drosos, K.C. Xarchas, C.N. Chatzipapas, C. Staikos</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>292</prism:startingPage> 
<prism:endingPage>294</prism:endingPage> 
<pubDate>2008-9-29</pubDate>
<category>Short Research Communication</category>
</item>

<item>
<link>http://www.medsci.org/v05p0285.htm</link> 
<title>EGFR Expression in Gallbladder Carcinoma in North America</title> 
<description><![CDATA[ <p>BACKGROUND: Increased epidermal growth factor receptor (EGF receptor) expression has been noted in various cancers and has become a useful target for therapeutic interventions. Small studies from Asia and Australia have demonstrated EGFR over-expression in gallbladder cancer. We sought to evaluate the expression of EGFR in a series of 16 gallbladder cancer patients from North America.</p> <p>METHODS: Using tumor registry data, we identified 16 patients diagnosed with gall bladder carcinoma at our medical center between the years of 1998 and 2005. We performed a retrospective review of these patients' charts, obtained cell blocks from pathology archives and stained for EGFR and Her2/neu.</p> <p>RESULTS: Fifteen of sixteen patients were noted to over-express EGFR. Three were determined 1+, nine were 2+ and three were 3+. Eight patients had poorly differentiated adenocarcinoma, six had moderately differentiated and two had well-differentiated tumors. In this small series, there was a trend toward shorter survival and more poorly differentiated tumors in patients with greater intensity of EGFR expression. One patient was EGFR negative but 3+ for erb-2/Her 2-neu expression. No patient co-expressed EGFR and Her-2-neu. Median survival of patients in this series was 17 months.</p> <p>CONCLUSION: In view of our observations confirming the over-expression of EGFR in our patient population in North America, and the recent success of EGFR targeted therapies in other solid tumors that over-express EGFR, it may now be appropriate to evaluate agents targeting this pathway either as single agents or in combination with standard chemotherapy.</p> ]]></description>  
<dc:creator>Matthew Kaufman, Bhoomi Mehrotra, Sewanti Limaye, Sherrie White, Alexander Fuchs, Yehuda Lebowicz, Sandy Nissel-Horowitz, Adrienne Thomas</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>285</prism:startingPage> 
<prism:endingPage>291</prism:endingPage> 
<pubDate>2008-9-22</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0273.htm</link> 
<title>TMZ-BioShuttle &#8211; a reformulated Temozolomide</title> 
<description><![CDATA[ <p>There is a large number of effective cytotoxic drugs whose side effect profile, efficacy, and long-term use in man are well understood and documented over decades of use in clinical routine e.g. in the treatment of recurrent glioblastoma multiforme (GBM) and the hormone-refractory prostate cancer (HRPC). Both cancers are insensitive against most chemotherapeutic interventions; they have low response rates and poor prognoses. Some cytotoxic agents can be significantly improved by using modern technology of drug delivery or formulation. We succeeded to enhance the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic temozolomide (TMZ) as an example. The TMZ connection to transporter molecules (TMZ-BioShuttle) resulted in a much higher pharmacological effect in glioma cell lines while using reduced doses. This permits the conclusion that a suitable chemistry could realize the ligation of pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The re-formulation of TMZ to TMZ-BioShuttle achieved a nearly 10-fold potential of the established pharmaceutic TMZ far beyond the treatment of brain tumors cells and results in an attractive reformulated drug with enhanced therapeutic index.</p> ]]></description>  
<dc:creator>Waldemar Waldeck, Manfred Wiessler, Volker Ehemann, Ruediger Pipkorn, Herbert Spring, Juergen Debus, Bernd Didinger, Gabriele Mueller, Joerg Langowski, Klaus Braun</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>273</prism:startingPage> 
<prism:endingPage>284</prism:endingPage> 
<pubDate>2008-9-15</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0263.htm</link> 
<title>Eph Receptors and Ephrin Signaling Pathways: A Role in Bone Homeostasis</title> 
<description><![CDATA[ <p>The maintenance of bone homeostasis is tightly controlled, and largely dependent upon cellular communication between osteoclasts and osteoblasts, and the coupling of bone resorption to bone formation. This tight coupling is essential for the correct function and maintenance of the skeletal system, repairing microscopic skeletal damage and replacing aged bone. A range of pathologic diseases, including osteoporosis and cancer-induced bone disease, disrupt this coupling and cause subsequent alterations in bone homeostasis. Eph receptors and their associated ligands, ephrins, play critical roles in a number of cellular processes including immune regulation, neuronal development and cancer metastasis. Eph receptors are also expressed by cells found within the bone marrow microenvironment, including osteoclasts and osteoblasts, and there is increasing evidence to implicate this family of receptors in the control of normal and pathological bone remodeling.</p> ]]></description>  
<dc:creator>Claire M. Edwards, Gregory R. Mundy</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>263</prism:startingPage> 
<prism:endingPage>272</prism:endingPage> 
<pubDate>2008-9-3</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0248.htm</link> 
<title>The usefulness of circulating adipokine levels for the assessment of obesity-related health problems</title> 
<description><![CDATA[ <p>Because the prevalence of obesity has increased dramatically in recent years, one of the key targets of public health is obesity and its associated pathological conditions. Obesity occurs as a result of white adipose tissue enlargement, caused by adipocyte hyperplasia and/or hypertrophy. Recently, endocrine aspects of adipose tissue have become an active research area and these adipose tissue-derived factors are referred to as adipokines. These adipokines interact with a range of processes in many different organ systems and influence a various systemic phenomena. Therefore, dysregulated production of adipokines has been found to participate in the development of metabolic and vascular diseases related to obesity. The obese state is also known to be associated with increased local and systemic inflammation. Adipokines influence not only systemic insulin resistance and have pathophysiological roles in the metabolic syndrome and cardiovascular disease, but also contribute toward an increase in local and systemic inflammation. Thus, circulating levels of adipokines can be used as high-throughput biomarkers to assess the obesity-related health problems, including low grade inflammation. This review focuses on the usefulness of measuring circulating adipokine levels for the assessment of obesity-related health problems.</p> ]]></description>  
<dc:creator>Hidekuni Inadera</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>248</prism:startingPage> 
<prism:endingPage>262</prism:endingPage> 
<pubDate>2008-8-29</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0244.htm</link> 
<title>Acceptability of cancer chemoprevention trials: impact of the design</title> 
<description><![CDATA[ <p><b>Background</b>: Chemoprevention could significantly reduce cancer burden. Assessment of efficacy and risk/benefit balance is at best achieved through randomized clinical trials.</p> <p><b>Methods</b>: At a periodic health examination center 1463 adults were asked to complete a questionnaire about their willingness to be involved in different kinds of preventive clinical trials.</p> <p><b>Results</b>: Among the 851 respondents (58.2%), 228 (26.8%) agreed to participate in a hypothetical chemoprevention trial aimed at reducing the incidence of lung cancer and 116 (29.3%) of 396 women agreed to a breast cancer chemoprevention trial. Randomization would not restrain participation (acceptability rate: 87.7% for lung cancer and 93.0% for breast cancer). In these volunteers, short-term trials (1 year) reached a high level of acceptability: 71.5% and 73.7% for lung and breast cancer prevention respectively. In contrast long-term trials (5 years or more) were far less acceptable: 9.2% for lung cancer (OR=7.7 CI<sub>95%</sub> 4.4-14.0) and 10.5 % for breast cancer (OR=6.9 CI<sub>95%</sub> 3.2-15.8). For lung cancer prevention, the route of administration impacts on acceptability with higher rate 53.1% for a pill vs. 7.9% for a spray (OR=6.7 CI<sub>95%</sub> 3.6-12.9).</p> <p><b>Conclusion</b>: Overall healthy individuals are not keen to be involved in chemo-preventive trials, the design of which could however increase the acceptability rate.</p> ]]></description>  
<dc:creator>Anne-Sophie Maisonneuve, Laetitia Huiart, Laetitia Rabayrol, Doug Horsman, Remi Didelot, Hagay Sobol, Francois Eisinger</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>244</prism:startingPage> 
<prism:endingPage>247</prism:endingPage> 
<pubDate>2008-8-22</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0240.htm</link> 
<title>IGF-1 regulates cAMP levels in astrocytes through a &#946;2-adrenergic receptor-dependant mechanism</title> 
<description><![CDATA[ <p>We have recently demonstrated that neonatal astrocytes derived from mice lacking beta-2 adrenergic receptors (&#946;<sub>2</sub>AR) possess higher proliferation rates, as compared to wild-type cells, an attribute that was shown to involve insulin-like growth factor (IGF) signaling. In the present study, we demonstrate that basal cAMP levels in &#946;<sub>2</sub>AR knockout astrocytes were significantly lower than in wild type cells. Furthermore, treatment with IGF-1 reduced intracellular cAMP levels in wild type astrocytes, yet had no effects on cAMP levels in &#946;<sub>2</sub>AR deficient astrocytes. Our data suggests that IGF-1 treatment influences cAMP production through a &#946;<sub>2</sub>AR-dependant mechanism in astrocytes. A deficit of &#946;<sub>2</sub>AR on astrocytes, as previously reported in multiple sclerosis, may influence cell proliferation, an action which could have implications in processes involved in astrogliosis.</p> ]]></description>  
<dc:creator>Daniel Chesik, Nadine Wilczak, Jacques De Keyser</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>240</prism:startingPage> 
<prism:endingPage>243</prism:endingPage> 
<pubDate>2008-8-6</pubDate>
<category>Short Research Communication</category>
</item>

<item>
<link>http://www.medsci.org/v05p0230.htm</link> 
<title>HIV-1 Capsid Assembly Inhibitor (CAI) Peptide: Structural Preferences and Delivery into Human Embryonic Lung Cells and Lymphocytes</title> 
<description><![CDATA[ <p>The Human immunodeficiency virus 1 derived capsid assembly inhibitor peptide (HIV-1 CAI-peptide) is a promising lead candidate for anti-HIV drug development. Its drawback, however, is that it cannot permeate cells directly. Here we report the transport of the pharmacologically active CAI-peptide into human lymphocytes and Human Embryonic Lung cells (HEL) using the BioShuttle platform. Generally, the transfer of pharmacologically active substances across membranes, demonstrated by confocal laser scanning microscopy (CLSM), could lead to a loss of function by changing the molecule's structure. Molecular dynamics (MD) simulations and circular dichroism (CD) studies suggest that the CAI-peptide has an intrinsic capacity to form a helical structure, which seems to be critical for the pharmacological effect as revealed by intensive docking calculations and comparison with control peptides. This coupling of the CAI-peptide to a BioShuttle-molecule additionally improved its solubility. Under the conditions described, the HIV-1 CAI peptide was transported into living cells and could be localized in the vicinity of the mitochondria.</p> ]]></description>  
<dc:creator>Klaus Braun, Martin Frank, R&#252;diger Pipkorn, Jennifer Reed, Herbert Spring, J&#252;rgen Debus, Bernd Didinger, Claus-Wilhelm von der Lieth, Manfred Wiessler, Waldemar Waldeck</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>5</prism:number> 
<prism:startingPage>230</prism:startingPage> 
<prism:endingPage>239</prism:endingPage> 
<pubDate>2008-7-31</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0224.htm</link> 
<title>Significant association between Helicobacter pylori infection and serum C-reactive protein</title> 
<description><![CDATA[ <p><b>Background: </b><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection in gastric mucosa may cause systemic inflammatory reaction. This study aimed to examine the association between the infection and serum high sensitivity C-reactive protein (hsCRP).</p> <p><b>Methods: </b>Subjects were comprised of three groups; 453 health checkup examinees from Yakumo town inhabitants in Hokkaido, Japan (YTI, 153 males and 300 females), 449 health checkup examinees (ENUH, 273 males and 176 females), and 255 female patients of an infertility clinic (PIC), Nagoya University Hospital. Twenty participants with hsCRP more than 1 mg/dl were excluded from the analysis. Those with hsCRP more than 0.1mg/dl were defined as high hsCRP individuals. <i>H. pylori</i> infection status was examined with a serum IgG antibody test.</p> <p><b>Results: </b>When the three groups were combined, the geometric mean of hsCRP concentration was significantly higher among the seropositives (0.047mg/dl) than among the seronegatives (0.035mg/dl); p&#60;0.0001 by a <i>t</i>-test. The percentage of high hsCRP individuals was also higher in the seropositives than in the seronegatives among any group; 23.3% and 20.1% in YTI, 22.0% and 16.0% in ENUH, and 32.7% and 18.7% in PIC, respectively, although the difference was significant only in ENUH. The summary odds ratio of the high hsCRP for the seropositives relative to the seronegatives was 1.38 (95% confidence interval, 1.01-1.89), when age, sex, body mass index, smoking, and subject group were adjusted by a logistic model.</p> <p><b>Conclusions</b>: In three groups, hsCRP was higher among the infected individuals. The summary odd ratio indicated that <i>H. pylori </i>infection could influence the serum hsCRP level.</p> ]]></description>  
<dc:creator>Yoshiko Ishida, Koji Suzuki, Kentaro Taki, Toshimitsu Niwa, Shozo Kurotsuchi, Hisao Ando, Akira Iwase, Kazuko Nishio, Kenji Wakai, Yoshinori Ito, Nobuyuki Hamajima</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>224</prism:startingPage> 
<prism:endingPage>229</prism:endingPage> 
<pubDate>2008-7-24</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0218.htm</link> 
<title>Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits</title> 
<description><![CDATA[ <p><b>Purpose: </b>In order to identify methods for preventing phlebitis caused by intravenous administration of vinorelbine (VNR), we established a procedure for estimating the severity of phlebitis in an animal model.</p> <p><b>Methods:</b> Four different factors (administration rate, dilution, flushing, and infusion of fat emulsion) were evaluated for alleviation of phlebitis caused by VNR infusion. VNR was diluted with normal saline to prepare test solutions with concentrations of 0.6 mg/mL or 0.3 mg/mL for infusion into the auricular veins of rabbits. Two days after VNR infusion, the veins were subjected to histopathological examination.</p> <p><b>Results: </b>VNR did not cause obvious loss of venous endothelial cells, the most sensitive and common feature of phlebitis, but VNR infusion led to inflammatory cell infiltration, edema, and epidermal degeneration.</p> <p>Tissue damage was significantly decreased by shortening the administration time and by diluting the VNR solution for infusion from 0.6 mg/mL to 0.3 mg/mL. However, there was no effect of flushing with normal saline after VNR infusion, while treatment with fat emulsion before and after VNR infusion only had a minimal effect.</p> <p><b>Conclusion:</b> Rapid infusion and dilution are effective methods of reducing phlebitis caused by the infusion of VNR, but the efficacy of flushing with normal saline or infusion of fat emulsion was not confirmed.</p> ]]></description>  
<dc:creator>Emiko Kohno, Saori Murase, Mayumi Nishikata, Noboru Okamura, Sumio Matzno, Takashi Kuwahara, Kenji Matsuyama</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>218</prism:startingPage> 
<prism:endingPage>223</prism:endingPage> 
<pubDate>2008-7-22</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0209.htm</link> 
<title>Molecular Predictors of EGFR-TKI Sensitivity in Advanced Non&#8211;small Cell Lung Cancer</title> 
<description><![CDATA[ <p>The epidermal growth factor receptor (EGFR) is overexpressed in the majority of non-small cell lung cancers (NSCLC) and is a major target for new therapies. Specific EGFR tyrosine kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. The clinical response, however, varies dramatically among different patient cohorts. Females, East Asians, non-smokers, and patients with adenocarcinoma usually show higher response rates. Meanwhile, a number of biological factors are also associated with EGFR-TKIs responsiveness. In order to better understand the predictive value of these biomarkers and their significance in clinical application we prepared this brief review. Here we mainly focused on <i>EGFR</i> somatic mutations, <i>MET</i> amplification, <i>K-ras</i> mutations, <i>EGFRvIII</i> mutation, <i>EGFR</i> gene dosage and expression, <i>HER2</i> gene dosage and expression, and Akt phosphorylation. We think <i>EGFR</i> somatic mutation probably is the most effective molecular predictor for EGFR-TKIs responsiveness and efficacy. Mutation screening test can provide the most direct and valuable guidance for clinicians to make decision on EGFR-TKIs therapy.</p> ]]></description>  
<dc:creator>Xiaozhu Zhang, Alex Chang</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>209</prism:startingPage> 
<prism:endingPage>217</prism:endingPage> 
<pubDate>2008-7-11</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0203.htm</link> 
<title>Contrast-Enhanced Ultrasonograpic Findings in Pancreatic Tumors</title> 
<description><![CDATA[ <p>OBJECTIVE: The purpose of this article is to present the potentials and limits of contrast-enhanced ultrasonography (CEUS) in the characterization of pancreatic tumors, usually hypoechoic or cystic at B-mode ultrasound.</p> <p>CONCLUSION: As regards hypoechoic lesions at B-mode ultrasound, CEUS often can distinguish among adenocarcinoma, islet cell tumor and serous microcystic adenoma. As regards cystic lesions, CEUS in most cases doesn't add significative diagnostic information; therefore CT, MR or endoscopic US are almost always necessary for their proper characterization.</p> ]]></description>  
<dc:creator>Chiara RECALDINI, Gianpaolo CARRAFIELLO, Elena BERTOLOTTI, Maria Gloria ANGERETTI, Carlo FUGAZZOLA</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>203</prism:startingPage> 
<prism:endingPage>208</prism:endingPage> 
<pubDate>2008-7-9</pubDate>
<category>Short Research Communication</category>
</item>

<item>
<link>http://www.medsci.org/v05p0197.htm</link> 
<title>BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases</title> 
<description><![CDATA[ <p>Breast cancer rates and median age of onset differ between Western Europe and North Africa. In Western populations, 5 to 10 % of breast cancer cases can be attributed to major genetic factors such as <i>BRCA1</i> and <i>BRCA2</i>, while this attribution is not yet well defined among Africans. To help determine the contribution of <i>BRCA1 </i>mutations to breast cancer in a North African population, we analysed genomic DNA from breast cancer cases ascertained in Algiers.</p> <p>Both familial cases (at least three breast cancers in the same familial branch, or two with one bilateral or diagnosed before age 40) and sporadic cases less than 38 years of age were studied. Complete sequencing plus quantitative analysis of the <i>BRCA1</i> gene was performed. 9.8 % (5/51) of early-onset sporadic and 36.4 % (4/11) of familial cases were found to be associated with <i>BRCA1</i> mutations. This is in contrast 10.3 % of French HBOC families exhibiting a <i>BRCA1</i> mutation. One mutation, c.798_799delTT, was observed in two Algerian families and in two families from Tunisia, suggesting a North African founder allele. Algerian non-<i>BRCA1</i> tumors were of significantly higher grade than French non-BRCA tumors, and the age at diagnosis for Algerian familial cases was much younger than that for French non-BRCA familial cases. In conclusion, we observed a much higher frequency of <i>BRCA1</i> mutations among young breast cancer patients than observed in Europe, suggesting biological differences and that the inclusion criterea for analysis in Western Europe may not be applicable for the Northern African population.</p> ]]></description>  
<dc:creator>Nancy Uhrhammer, Amina Abdelouahab, Laurence Lafarge, Viviane Feillel, Ahmed Ben Dib, Yves-Jean Bignon</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>197</prism:startingPage> 
<prism:endingPage>202</prism:endingPage> 
<pubDate>2008-7-8</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0189.htm</link> 
<title>Iodine Alters Gene Expression in the MCF7 Breast Cancer Cell Line: Evidence for an Anti-Estrogen Effect of Iodine</title> 
<description><![CDATA[ <p>The protective effects of iodine on breast cancer have been postulated from epidemiologic evidence and described in animal models. The molecular mechanisms responsible have not been identified but laboratory evidence suggests that iodine may inhibit cancer promotion through modulation of the estrogen pathway. To elucidate the role of iodine in breast cancer, the effect of Lugol's iodine solution (5% I<sub>2</sub>, 10% KI) on gene expression was analyzed in the estrogen responsive MCF-7 breast cancer cell line. Microarray analysis identified 29 genes that were up-regulated and 14 genes that were down-regulated in response to iodine/iodide treatment. The altered genes included several involved in hormone metabolism as well as genes involved in the regulation of cell cycle progression, growth and differentiation. Quantitative RT-PCR confirmed the array data demonstrating that iodine/iodide treatment increased the mRNA levels of several genes involved in estrogen metabolism (CYP1A1, CYP1B1, and AKR1C1) while decreasing the levels of the estrogen responsive genes TFF1 and WISP2. This report presents the results of the first gene array profiling of the response of a breast cancer cell line to iodine treatment. In addition to elucidating our understanding of the effects of iodine/iodide on breast cancer, this work suggests that iodine/iodide may be useful as an adjuvant therapy in the pharmacologic manipulation of the estrogen pathway in women with breast cancer.</p> ]]></description>  
<dc:creator>Frederick R. Stoddard II, Ari D. Brooks, Bernard A. Eskin, Gregg J. Johannes</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>189</prism:startingPage> 
<prism:endingPage>196</prism:endingPage> 
<pubDate>2008-7-8</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0181.htm</link> 
<title>Receipt of Standard Breast Cancer Treatment by African American and White Women</title> 
<description><![CDATA[ <p><b>Objectives</b>: Breast cancer mortality is higher among African Americans than for Whites, though their breast cancer incidence is lower. This study examines whether this disparity may be due to differential receipt of treatment defined as &#8220;standard of care&#8221; or &#8220;addition to standard of care&#8221; by the National Comprehensive Cancer Network (NCCN).</p> <p><b>Design</b>: Incident, female breast cancer cases, 2,203 African American and 7,518 White, diagnosed during 1996-2002 were identified from the Alabama Statewide Cancer Registry. Breast cancer treatment was characterized as whether or not a woman received standard of care as defined by the NCCN. For cases characterized as receiving standard of care, addition to standard of care was also evaluated, defined as receiving at least one additional treatment modality according to NCCN guidelines. Logistic models were used to evaluate racial differences in standard and addition to standard of care and to adjust for age, stage at diagnosis, year of diagnosis and area of residence.</p> <p><b>Results</b>: No racial differences were found for standard (Prevalence Ratio (PR)=1.00) or for addition to standard of care (PR=1.00) after adjustment for confounders<b>.</b> When the adjusted models were examined separately by age, stage, and area of residence, overall no racial differences were found.</p> <p><b>Conclusion</b>: No racial differences in standard of care and addition to standard of care for breast cancer treatment were found. Therefore, both African Americans and Whites received comparable treatment according to NCCN guidelines.</p> ]]></description>  
<dc:creator>Julie Worthington, John W. Waterbor, Ellen Funkhouser, Carla Falkson, Stacey Cofield, Mona Fouad</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>181</prism:startingPage> 
<prism:endingPage>188</prism:endingPage> 
<pubDate>2008-7-7</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0169.htm</link> 
<title>Infliximab and Etanercept Are Equally Effective in Reducing Enterocyte APOPTOSIS in Experimental Colitis</title> 
<description><![CDATA[ <p>Loss of epithelial barrier integrity is considered an early step in the pathogenesis of Crohn's disease (CD), and the rate of enterocyte apoptosis is one of the determinants of the intestinal barrier function. Tumor necrosis factor-&#945; (TNF-&#945;), one of the major proinflammatory mediators in CD, is one of the extrinsic signals which initiate apoptosis of enterocytes. The aim of this study was to investigate the early effects of experimental colitis on enterocyte apoptosis, and the effects of two anti-TNF treatments, infliximab (IFX) and etanercept (ETC). In addition, the importance of receptor I for TNF was tested in TNFR-1<sup>-/- </sup>mice.</p> <p>Circulating TNF-&#945; levels were effectively reduced by IFX and ETC (p&#60;0.01, both) at 3 and 6 h. Apoptosis of the ileal enterocytes, assessed by TUNEL staining, staining for Fas-ligand, and bax, increased at 3 and 6h. These alterations were prevented by both anti-TNF strategies, and in TNFR-1<sup>-/-</sup> animals. The anti-apoptotic protein Bcl-2 was expressed in the ileal epithelium under control conditions, but was suppressed in DNB-colitis. Expression of Bcl-2 was maintained in both anti-TNF treatments and TNFR-1<sup>-/-</sup> mice.</p> <p>DNB colitis induced a very early, rapid increase of enterocyte apoptosis. Both anti-TNF strategies, IFX and ETC, were equally effective in suppressing enterocyte apoptosis, most likely by inactivation of circulating TNF-&#945;.</p> ]]></description>  
<dc:creator>Walter Fries, Carmelo Muja, Carmela Crisafulli, Giuseppe Costantino, Giuseppe Longo, Salvatore Cuzzocrea, Emanuela Mazzon</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>4</prism:number> 
<prism:startingPage>169</prism:startingPage> 
<prism:endingPage>180</prism:endingPage> 
<pubDate>2008-7-3</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0159.htm</link> 
<title>Ethical Perspectives on RNA Interference Therapeutics</title> 
<description><![CDATA[ <p>RNA interference is a mechanism for controlling normal gene expression which has recently begun to be employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious diseases and metabolic disorders. Clinical trials with RNA interference have begun. However, challenges such as off-target effects, toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a conventional drug. So, if RNA interference is to be used therapeutically, we should perform a risk-benefit analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not only include a risk-benefit analysis, but also considerations about respecting the autonomy of the patient and considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care allocation. RNA interference is considered a new and promising therapeutic approach, but the ethical issues of this method have not been greatly discussed, so this article analyses these issues using the bioethical theory of principles of the American bioethicists, Tom L. Beauchamp and James F. Childress.</p> ]]></description>  
<dc:creator>Mette Ebbesen, Thomas G. Jensen, Svend Andersen, Finn Skou Pedersen</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>159</prism:startingPage> 
<prism:endingPage>168</prism:endingPage> 
<pubDate>2008-6-25</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0152.htm</link> 
<title>Of rodents and humans: a light microscopic and ultrastructural study on cardiomyocytes in pulmonary veins</title> 
<description><![CDATA[ <p>Cardiomyocytes in pulmonary veins (PVs) have been reported in rodents and humans. In humans they were related to atrial arrhythmias, including atrial fibrillation (AF). To investigate histological similarities and differences in PV cardiomyocyte localization and distribution, we performed comparative light and electron microscopic studies on humans, rats and mice, and generated a transgenic mouse strain. Results on mice (C57BL/6 and BALBc) and rats (Wistar) revealed that cardiomyocytes regularly extend from the hilus along venous vessels into the lung tissue surrounding individual intrapulmonary veins of varying diameters (70-250&#181;m). The cardiomyocytes showed the ultrastructure of a normal working myocardium with intact intercalated discs and tightly packed contractile filaments. In both lung and hilus cardiomyocytes were localized either close to the basal lamina of the endothelium or separated from it by smooth muscle cells and/or collagen fibres. In humans (autopsies, n=20) extrapericardiac cardiomyocytes were only found in 23 out of 78 veins and showed an incomplete sleeve at the lung hilus. In addition, cardiomyocytes occurred significantly more often in right than in left veins, however, never in intrapulmonary veins.</p> <p>We discuss the hypothesis that the variance in distribution of PV cardiomyocytes in humans and rodents might reflect the difference in pathogenesis and development of AF.</p> ]]></description>  
<dc:creator>Josef Mueller-Hoecker, Frigga Beitinger, Borja Fernandez, Olaf Bahlmann, Gerald Assmann, Christian Troidl, Ilias Dimomeletis, Stefan K&#228;&#228;b, Elisabeth Deindl</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>152</prism:startingPage> 
<prism:endingPage>158</prism:endingPage> 
<pubDate>2008-6-24</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0143.htm</link> 
<title>OXIDATIVE PHOSPHORYLATION: Kinetic and Thermodynamic Correlation between Electron Flow, Proton Translocation, Oxygen Consumption and ATP Synthesis under Close to In Vivo Concentrations of Oxygen</title> 
<description><![CDATA[ <p>For the fist time the mitochondrial process of oxidative phosphorylation has been studied by determining the extent and initial rates of electron flow, H<sup>+</sup> translocation, O<sub>2</sub> uptake and ATP synthesis under close to in vivo concentrations of oxygen. The following novel results were obtained. 1) The real rates of O<sub>2</sub> uptake and ATP synthesis are orders of magnitude higher than those observed under state-3 metabolic conditions. 2) The phosphorylative process of ATP synthesis is neither kinetically nor thermodynamically related to the respiratory process of H<sup>+</sup> ejection. 3) The ATP/O stoichiometry is not constant but varies depending on all, the redox potential (<i>&#916;E<sub>h</sub></i>), the degree of reduction of the membrane and the relative concentrations of O<sub>2</sub>, ADP, and protein. 4) The free energy of electron flow is not only used for the enzymatic binding and release of substrates and products but fundamentally for the actual synthesis of ATP from ADP and Pi. 5) The concentration of ADP that produces half-maximal responses of ATP synthesis (<i>EC<sub>50</sub></i>) is not constant but varies depending on both <i>&#916;E<sub>h</sub></i> and O<sub>2</sub> concentration. 6) The process of ATP synthesis exhibits strong positive catalytic cooperativity with a Hill coefficient, <i>n,</i> of &#126;3.0. It is concluded that the most important factor in determining the extent and rates of ATP synthesis is not the level of ADP or the proton gradient but the concentration of O<sub>2</sub> and the state of reduction and/or protonation of the membrane.</p> ]]></description>  
<dc:creator>Baltazar D. Reynafarje, Jorge Ferreira</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>143</prism:startingPage> 
<prism:endingPage>151</prism:endingPage> 
<pubDate>2008-6-9</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0133.htm</link> 
<title>Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer</title> 
<description><![CDATA[ <p>Objectives. To find potential diagnostic markers or therapeutic targets, we used differential display technique to identify genes that are over or under expressed in human ovarian cancer.</p> <p>Methods. Genes were initially identified by differential display between two human ovarian surface epithelium cultures and two ovarian cancer cell lines, A2780 and Caov-3. Genes were validated by relative quantitative RT-PCR and RNA <i>in situ</i> hybridization.</p> <p>Results. Twenty-eight non-redundant sequences were expressed differentially in the normal ovarian epithelium and ovarian cancer cell lines. Seven of the 28 sequences showed differential expression between normal ovary and ovarian cancer tissue by RT-PCR. USP36 was over-expressed in ovarian cancer cell lines and tissues by RT-PCR and RNA <i>in situ</i> hybridization. Northern blot analysis and RT-PCR revealed two transcripts for USP36 in ovarian tissue. The major transcript was more specific for ovarian cancer and was detected by RT-PCR in 9/9 ovarian cancer tissues, 3/3 cancerous ascites, 5/14 (36%) sera from patients with ovarian cancer, and 0/7 sera from women without ovarian cancer.</p> <p>Conclusion. <i>USP36 </i>is overexpressed in ovarian cancer compared to normal ovary and its transcripts were identified in ascites and serum of ovarian cancer patients.</p> ]]></description>  
<dc:creator>Jianduan Li, Lisa M. Olson, Zhengyan Zhang, Lina Li, Miri Bidder, Loan Nguyen, John Pfeifer, Janet S. Rader</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>133</prism:startingPage> 
<prism:endingPage>142</prism:endingPage> 
<pubDate>2008-6-6</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0127.htm</link> 
<title>Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells</title> 
<description><![CDATA[ <p>The pathogenesis of neurological diseases and disorders remains mostly unknown. Neuroinflammation has been proposed as a causative factor for neurological diseases. The confirmation that neurogenesis occurs in the adult brain and neural stem cells (NSCs) reside in the adult central nervous system (CNS) of mammals has tremendous implications for our understanding of the physio- and pathology of the nervous system. The generation of newborn neuronal cells in the adult brain is modulated in neurological diseases and during inflammation. This suggests that adult neurogenesis is involved in the pathogenesis of neurological diseases and disorders, particularly during neuroinflammation. In this manuscript, we will review the modulation of adult neurogenesis in neurological diseases and during neuroinflammation. We will discuss the role and contribution of neuroinflammation and adult neurogenesis to neurological diseases and disorders, and for the therapeutic potential of adult NSCs.</p> ]]></description>  
<dc:creator>Philippe Taupin</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>127</prism:startingPage> 
<prism:endingPage>132</prism:endingPage> 
<pubDate>2008-6-5</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0121.htm</link> 
<title>Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis</title> 
<description><![CDATA[ <p>By using immunohistochemistry we investigated the expression of EphA2 and EphrinA-1 in 217 early squamous cell cervical carcinomas and examine their prognostic relevance. For EphA2 expression, 21 tumors (10%) showed negative, 108 (50%) weak positive, 69 (32%) moderate positive and 19 (9%) strong positive, whereas for EphrinA-1 expression, 33 tumors (15%) showed negative, 91 (42%) weak positive, 67 (31%) moderate positive and 26 (12%) strong positive. In univariate analysis high expression (strong staining) of EphrinA-1 was associated with poor disease-free (<i>P</i> = 0.033) and disease-specific (<i>P</i> = 0.039) survival. However, in the multivariate analyses neither EphrinA-1 nor EphA2 was significantly associated to survival. The increased levels of EphA2 and EphrinA-1 in a relative high number of early stage squamous cell carcinomas suggested that these two proteins may play an important role in the development of a subset of early cervical cancers. However, EphA2 and EphrinA-1 were not independently associated with clinical outcome.</p> ]]></description>  
<dc:creator>Ruth Holm, Gregg Van de Putte, Zhenhe Suo, A Kathrine Lie, Gunnar B Kristensen</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>121</prism:startingPage> 
<prism:endingPage>126</prism:endingPage> 
<pubDate>2008-6-5</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0113.htm</link> 
<title>The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition</title> 
<description><![CDATA[ <p>Purpose: To evaluated prognostic factors and impact of the quality of planning of high dose rate brachytherapy (HDR-BT) for patients with local or locally advanced prostate cancer treated with external beam radiotherapy (EBRT) and HDR-BT.</p> <p>Methods and Materials: Between 1997 and 2005, 209 patients with biopsy proven prostate adenocarcinoma were treated with localized EBRT and HDR-BT at the Department of Radiation-Oncology, Hospital A. C. Camargo, Sao Paulo, Brazil. Patient's age, Gleason score (GS), clinical stage (CS), initial PSA (iPSA), risk group for biochemical failure (GR), doses of EBRT and HDR-BT, use of three-dimensional planning for HDR-BT (3DHDR) and the Biological Effective Dose (BED) were evaluated as prognostic factors for biochemical control (bC).</p> <p>Results: Median age and median follow-up time were 68 and 5.3 years, respectively. Median EBRT and HDR-BT doses were 45 Gy and 20 Gy. The crude bC at 3.3 year was 94.2%. For the Low, intermediate and high risk patients the bC rates at 3.3 years were 91.5%, 90.2% and 88.5%, respectively. Overall survival (OS) and disease specific survival rates at 3.3 years were 97.8% and 98.4%, respectively. On univariate analysis the prognostic factors related bC were GR (p= 0.040), GS &#8804; 6 (p= 0.002), total dose of HDR-BT &#8805; 20 Gy (p&#60; 0.001), 3DHDR (p&#60; 0.001), BED-HDR &#8805; 99 Gy<sub>1.5</sub> (p&#60;0.001) and BED-TT &#8805; 185 (p&#60;0.001). On multivariate analysis the statistical significant predictive factors related to bC were RG (p&#60; 0.001), HDR-BT &#8805; 20 Gy (p=0.008) and 3DHDR (p&#60;0.001).</p> <p>Conclusions: we observed that the bC rates correlates with the generally accepted risk factors described in the literature. Dose escalation, evaluated through the BED, and the quality of planning of HDR-BT are also important predictive factors when treating prostate cancer.</p> ]]></description>  
<dc:creator>Antonio Cassio Assis Pellizzon, Jo&#227;o Salvajoli, Paulo Novaes, Maria Maia, Ricardo Fogaroli, Doglas Gides, Rodrigues Horriot</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>113</prism:startingPage> 
<prism:endingPage>120</prism:endingPage> 
<pubDate>2008-6-4</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0106.htm</link> 
<title>Breast cancer screening in France: results of the EDIFICE survey</title> 
<description><![CDATA[ <p><b>Background</b>: The EDIFICE survey aimed to investigate the compliance of the general population to the screening tests available in France for the 4 most common cancers: breast, colorectal, prostate and lung. Implementation of breast cancer screening has been generalized in France since 2003: women aged between 50 and 74 years are systematically invited to perform a mammography every second year. Results pertaining to breast cancer are reported hereafter.</p> <p><b>Methods</b>: This nationwide observational survey was carried out in France from 18 January to 2 February 2005 among representative samples of 773 women aged between 40 and 75 years and 600 general practitioners (GPs). Information collected included socio-demographic characteristics, attitude towards cancer screening and actual experience of cancer screening, as well as GPs' practice regarding screening. The precision of the results is &#177; 4.3% for a 95% confidence interval.</p> <p><b>Results</b>: Among the 507 participating women aged between 50 and 74 years, 92.5% (469/507) had undergone at least one mammography: 54.6% (256/469) underwent this test on their own initiative and 44.6% (209/469) of women performed it in the framework of a systematic screening plan. Most women participating in the systematic screening (89.0% i.e. 186/209) had a mammography within the last dating from less than 2 years <i>versus</i> 73.8% (189/256) of those who performed it outside the screening program (Chi<sup>2</sup> test; p&#60;0.01). Interestingly, 422 women (61.9% i.e. 422/682 women aged between 40-75 years with at least one mammography) had performed a mammography before the recommended age for screening. There was a significant correlation (p = 0.009) between the existence of a first mammography before 50 years of age and subsequent screening on women's own initiative (54.6% of 469 screened women). Main reasons for not performing the screening test every second year (77 women aged between 50-74 years) included: feeling unconcerned and/or unmotivated (p = 0.0001), no cancer anxiety (p = 0.020) and no recommendation by the GP (p = 0.015); Of the 600 participating GPs, 68.6% (412/600) systematically recommended a mammography to their patients. GPs' perceptions of the reasons for women's avoidance of the screening test were unwillingness to be aware of mammography results (44.4% - 266/600) and the belief that mammography was painful (52.5% - 315/600).</p> <p><b>Conclusion</b>: The main result of the EDIFICE survey is the high rate of women's attendance at mammography screening. The EDIFICE survey pointed out that systematic and organized screening played a major role in the regularity of screening tests for breast cancer every second year. GPs and gynaecologist are key actors in heightening public awareness.</p> ]]></description>  
<dc:creator>X Pivot, O Rixe, JF Morere, Y Coscas, L Cals, M Namer, D Serin, S Dolbeault, F Eisinger, C Roussel, JY Blay</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>3</prism:number> 
<prism:startingPage>106</prism:startingPage> 
<prism:endingPage>112</prism:endingPage> 
<pubDate>2008-5-24</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0100.htm</link> 
<title>MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER</title> 
<description><![CDATA[ <p>The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in patients with positive tumour hormone receptor status. The patients with early disease progression during first-line chemotherapy were not included. In total, 560 patients who achieved a stable disease or a response to first-line chemotherapy were studied. The factors identified to improve the duration of PFS or OS in multivariate analysis were: number of metastatic sites (p = .01; p = .01), metastatic sites (p = .02; p = .04), Disease free interval (p = .001; p &#60; .0001), previous hormonal therapy (p = .03; p = ns), response to first line chemotherapy (p &#60; .0001; p = 0.0001) and an administration of maintenance hormonal therapy (p &#60; .0001; p = .001). The major impact obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that this strategy should be recommended in patients with an ER or PgR positive tumour.</p> ]]></description>  
<dc:creator>Armelle Dufresne, Xavier Pivot, Christophe Tournigand, Thomas Facchini, Thierry Alweeg, Loic Chaigneau, Aimery De Gramont</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>100</prism:startingPage> 
<prism:endingPage>105</prism:endingPage> 
<pubDate>2008-5-5</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0092.htm</link> 
<title>Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis</title> 
<description><![CDATA[ <p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. Previous proteomic evidence revealed that the content of certain peptide fragments including Vgf-derived peptide aa 398-411 (Vgf<sub>398-411</sub>) of the precursor Vgf protein in the cerebral spinal fluid (CSF) correctly identified patients with ALS from normal and disease controls. Using quantitative ELISA immunoassay we found that the CSF levels of Vgf decreases with muscle weakness in patients with ALS. In SOD1 G93A transgenic mice, loss of full-length Vgf content in CSF, serum and in SMI-32 immunopositive spinal cord motor neurons is noted in asymptomatic animals (approximately 75 days old) and continues to show a progressive decline as animals weaken. In vitro studies show that viral-mediated exogenous Vgf expression in primary mixed spinal cord neuron cultures attenuates excitotoxic injury. Thus, while Vgf may be a reliable biomarker of progression of muscle weakness in patients with ALS, restoration of Vgf expression in spinal cord motor neurons may therapeutically rescue spinal cord motorneurons against excitotoxic injury.</p> ]]></description>  
<dc:creator>Zhong Zhao, Dale J. Lange, Lap Ho, Sara Bonini, Belinda Shao, Stephen R. Salton, Sunil Thomas, Giulio Maria Pasinetti</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>92</prism:startingPage> 
<prism:endingPage>99</prism:endingPage> 
<pubDate>2008-4-15</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0087.htm</link> 
<title>TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders</title> 
<description><![CDATA[ <p>Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 receptor (sIL-6R) in relation to response to treatment with and plasma concentrations of anagrelide. Samples from 45 patients with thrombocythemia due to MPD (ET=31, PV=14), being treated with anagrelide for 6 months, were analyzed for TPO, sIL-6R and anagrelide levels. The mean baseline platelet count was 983x10<sup>9</sup>/L. A reduction of platelets to &#60;600 in asymptomatic or &#60;400 x 10<sup>9</sup>/L in symptomatic patients was defined as a complete remission (CR), a reduction with &#62;50% of baseline as partial remission, and &#60;50% reduction as failure. At 6 months, 35 patients were in CR, 1 had a partial remission and 9 were treatment failures. For all patients, there was an increase in TPO of 44% from baseline; this change was more pronounced for patients with partial remission and failure. sIL-6R levels did not change significantly. There was no correlation between levels of anagrelide and cytokine levels at 6 months, and changes of cytokine levels did not relate to changes of platelet counts. Thus, a pronounced increase of TPO levels after 6 months of anagrelide treatment indicated that this treatment affected a major regulatory mechanism for megakaryocyte and platelet formation in MPD.</p> ]]></description>  
<dc:creator>Jan Palmblad, Magnus Bj&#246;rkholm, Jack Kutti, Gerd L&#228;rfars, Eva L&#246;fvenberg, Berit Markev&#228;rn, Mats Merup, Nils Mauritzson, Jan Westin, Jan Samuelsson, Gunnar Birgeg&#229;rd</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>87</prism:startingPage> 
<prism:endingPage>91</prism:endingPage> 
<pubDate>2008-4-13</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0080.htm</link> 
<title>VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese</title> 
<description><![CDATA[ <p>Background: Previously, <i>MDR1 </i>T-129C polymorphism, encoding multidrug resistant transporter MDR1/P-glycoprotein, was reported to be predictive of poorly-differentiated colorectal adenocarcinomas. Here,<i> VEGF</i> T-1498C, C-634G and C-7T polymorphisms, encoding vascular endothelial growth factor (VEGF), were investigated in terms of their association with differentiation grade.</p> <p>Methods: <i>VEGF</i> genotypes were determined by TaqMan<sup>R</sup> MGB probe based polymerase chain reaction and evaluated were confirmed by direct sequencing in 36 Japanese patients.</p> <p>Results: <i>VEGF</i> T-1498C, but not C-634G or C-7T, was predictive of poorly-differentiated ones, and thereby a poor prognosis (p = 0.064 for genotype, p = 0.037 for allele), and this effect can be explained by that on VEGF expression. Treatment of a colorectal adenocarcinoma cell line, HCT-15, with sodium butyrate, a typical differentiating agent, resulted in an increase of alkaline phosphatase activity and MDR1 mRNA expression, but in a decrease of VEGF mRNA expression. The transfection of VEGF small interfering RNA (siRNA) induced the expression of MDR1 mRNA to 288-332% of the control level, whereas MDR1 siRNA had no effect on VEGF mRNA expression.</p> <p>Conclusions: <i>VEGF</i> T-1498C polymorphism is also a candidate marker predictive of poorly-differentiated colorectal adenocarcinomas, but further investigations with a large number of patients should be addressed to draw a conclusion.</p> ]]></description>  
<dc:creator>Motohiro Yamamori, Mayuko Taniguchi, Shingo Maeda, Tsutomu Nakamura, Noboru Okamura, Akiko Kuwahara, Koichi Iwaki, Takao Tamura, Nobuo Aoyama, Svetlana Markova, Masato Kasuga, Katsuhiko Okumura, Toshiyuki Sakaeda</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>80</prism:startingPage> 
<prism:endingPage>86</prism:endingPage> 
<pubDate>2008-4-8</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0073.htm</link> 
<title>Expression and function of micro RNAs in immune cells during normal or disease state</title> 
<description><![CDATA[ <p>Micro RNAs (miRNAs) are 19-24 nucleotide long non-coding RNAs that posttranscriptionally modulate gene expression. They are found in almost all species: viruses, plants, nematodes, fly, fish, mouse, human, and are implicated in a wide array of cellular and developmental processes. Microarray-based miRNA profiling brought to the discovery of miRNAs specific to different hematopoietic lineages. Furthermore, the functional assays performed in tissue cultures to discover miRNAs involved in immune responses in combination with the reports of miRNA-transgenic or miRNA-knockout mouse models has helped elucidating the miRNA roles in the development and function of immune system. Abnormal patterns of hematopoietic-specific miRNAs have been found in different types of cancer and miRNA based gene therapy is being considered as a potential technology of choice in immunological disorders and cancer. The purpose of this review is to discuss recent findings related with the expression and function of miRNAs in hematopoietic lineages.</p> ]]></description>  
<dc:creator>Esmerina Tili, Jean-Jacques Michaille, George Adrian Calin</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>73</prism:startingPage> 
<prism:endingPage>79</prism:endingPage> 
<pubDate>2008-4-3</pubDate>
<category>Review</category>
</item>

<item>
<link>http://www.medsci.org/v05p0068.htm</link> 
<title>Principal Investigator Views of the IRB System</title> 
<description><![CDATA[ <p>We undertook a qualitative e-mail survey of federally-funded principal investigators of their views of the US human subjects protection system, intended to identify the range of investigator attitudes. This was an exploratory study with a 14% response rate. Twenty-eight principal investigators responded; their comments were analyzed to show underlying themes, which are here presented along with supporting quotations.</p> <p>There was consensus that it is important to protect human subjects from research abuse, but disagreement over how well the IRB system is functioning. Some researchers felt that the system is effective and serves its purpose well. Of those who support the system, some endorse its methods, purpose, and daily functioning, as they experience it, without reservation. Others, while expressing some frustration, feel that the purpose is important and their local IRB does its best to make a difficult system work well.</p> <p>Those investigators who were more harshly critical commented on multiple flaws in the system, including (1) consent forms that are inappropriate and incomprehensible, (2) an emphasis on minutiae, and (3) concern with protecting the institution more than research subjects. Respondents told us that the IRB system is a particular burden for research in neurology, emergency medical conditions, repositories, and social sciences in general; a more comprehensive study might identify other problematic areas. Significant concern was expressed about the cost, inefficiency, and irrationality of IRB review. The IRB system works well for some researchers, but our results indicate that other investigators feel the costs outweigh the benefits.</p> ]]></description>  
<dc:creator>Simon N. Whitney, Kirsten Alcser, Carl E. Schneider, Laurence B. McCullough, Amy L. McGuire, Robert J. Volk</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>68</prism:startingPage> 
<prism:endingPage>72</prism:endingPage> 
<pubDate>2008-4-2</pubDate>
<category>Short Research Communication</category>
</item>

<item>
<link>http://www.medsci.org/v05p0062.htm</link> 
<title>A 12 Week, Open Label, Phase I/IIa Study Using Apatone&#174; for the Treatment of Prostate Cancer Patients Who Have Failed Standard Therapy</title> 
<description><![CDATA[ <p><b>Purpose</b>: To evaluate the safety and efficacy of oral Apatone<b><sup>&#174;</sup></b> (Vitamin C and Vitamin K<sub>3</sub>) administration in the treatment of prostate cancer in patients who failed standard therapy.</p> <p><b>Materials and Methods</b>: Seventeen patients with 2 successive rises in PSA after failure of standard local therapy were treated with (5,000 mg of VC and 50 mg of VK<sub>3</sub> each day) for a period of 12 weeks. Prostate Specific Antigen (PSA) levels, PSA velocity (PSAV) and PSA doubling times (PSADT) were calculated before and during treatment at 6 week intervals<b>. </b>Following the initial 12 week trial, 15 of 17 patients opted to continue treatment for an additional period ranging from 6 to 24 months. PSA values were followed for these patients.</p> <p><b>Results</b>: At the conclusion of the 12 week treatment period, PSAV decreased and PSADT increased in 13 of 17 patients (p &#8804; 0.05). There were no dose-limiting adverse effects. Of the 15 patients who continued on Apatone after 12 weeks, only 1 death occurred after 14 months of treatment.</p> <p><b>Conclusion</b>: Apatone showed promise in delaying biochemical progression in this group of end stage prostate cancer patients.</p> ]]></description>  
<dc:creator>Basir Tareen, Jack L. Summers, James M. Jamison, Deborah R. Neal, Karen McGuire, Lowell Gerson, Ananias Diokno</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>62</prism:startingPage> 
<prism:endingPage>67</prism:endingPage> 
<pubDate>2008-3-24</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0050.htm</link> 
<title>Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis after coronary revascularization</title> 
<description><![CDATA[ <p><i>Background</i>: Resting electrocardiogram (ECG) shows limited sensitivity and specificity for the detection of coronary artery disease (CAD), where patients with a history of coronary revascularization may pose special challenges. Several methods exist to enhance sensitivity and specificity of resting ECG for diagnosis of CAD, but such methods are not better than a specialist's judgement. We compared a new computer-enhanced, resting ECG analysis device, 3DMP, to coronary angiography to evaluate the device's accuracy in detecting hemodynamically relevant CAD.</p> <p><i>Methods</i>: A convenience sample of 172 patients with a history of coronary revascularization scheduled for coronary angiography was evaluated with 3DMP before coronary angiography. 3DMP's sensitivity and specificity in detecting hemodynamically relevant coronary stenosis as diagnosed with coronary angiography were calculated as well as odds ratios for the 3DMP severity score and coronary artery disease risk factors.</p> <p><i>Results</i>: The 3DMP system accurately identified 50 of 55 patients as having hemodynamically relevant stenosis (sensitivity 90.9%, specificity 88.0%). Positive and negative predictive values for the identification of coronary stenosis as diagnosed in coronary angiograms were 62.7% and 97.8% respectively. Risk and demographic factors in a logistic regression model had a markedly lower predictive power for the presence of coronary stenosis in these patients than did 3DMP severity score (odds ratio 2.04 [0.74-5.62] vs. 73.57 [25.10-215.68]). A logistic regression combining severity score with risk and demographic factors did not add significantly to the prediction quality (odds ratio 80.00 [27.03-236.79]).</p> <p><i>Conclusions</i>: 3DMP's computer-based, mathematically derived analysis of resting two-lead ECG data provides detection of hemodynamically relevant CAD in patients with a history of coronary revascularization with high sensitivity and specificity that appears to be at least as good as those reported for other resting and/or stress ECG methods currently used in clinical practice.</p> ]]></description>  
<dc:creator>Eberhard Grube, Andreas Bootsveld, Lutz Buellesfeld, Seyrani Yuecel, Joseph T Shen, Michael Imhoff</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>2</prism:number> 
<prism:startingPage>50</prism:startingPage> 
<prism:endingPage>61</prism:endingPage> 
<pubDate>2008-3-2</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0041.htm</link> 
<title>Qualitative Dosimetric and Radiobiological Evaluation of High &#8211; Dose &#8211; Rate Interstitial brachytherapy Implants</title> 
<description><![CDATA[ <p>Radiation quality indices (QI), tumor control probability (TCP), and normal tissue complication probability(NTCP) were evaluated for ideal single and double plane HDR interstitial implants. In the analysis, geometrically&#8211;optimized at volume (GOV) treatment plans were generated for different values of inter&#8211;source&#8211;spacing (ISS) within the catheter, inter&#8211;catheter&#8211;spacing (ICS), and inter&#8211;plane&#8211;spacing (IPS) for single - and double - plane implants. The dose volume histograms (DVH) were generated for each plan, and the coverage volumes of 100%, 150%, and 200% were obtained to calculate QIs, TCP, and NTCP. Formulae for biologically effective equivalent uniform dose (BEEUD), for tumor and normal tissues, were derived to calculate TCP and NTCP. Optimal values of QIs, except external volume index (EI), and TCP were obtained at ISS = 1.0 cm, and ICS = 1.0 cm, for single&#8211;plane implants, and ISS = 1.0 cm, ICS = 1.0 cm, and IPS = 0.75 to 1.25 cm, for double &#8211; plane implants. From this study, it is assessed that ISS = 1.0 cm, ICS = 1.0 cm, for single - plane implant and IPS between 0.75 cm to 1.25 cm provide better dose conformity and uniformity.</p> ]]></description>  
<dc:creator>Than S. Kehwar, Syed F. Akber, Kamlesh Passi</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>41</prism:startingPage> 
<prism:endingPage>49</prism:endingPage> 
<pubDate>2008-2-19</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0036.htm</link> 
<title>Correlation of the Radiographic and Morphological Features of the Dental Follicle of Third Molars with Incomplete Root Formation</title> 
<description><![CDATA[ <p>The objective of this study was to determine the correlation of the radiographic and morphological features of the dental follicle of unerupted third molars with incomplete root formation. A cross-sectional study was carried out with 56 patients (105 teeth) aged 13 to 24 years. Panoramic radiography was used to determine the stage of root formation to locate and measure pericoronal radiolucency. The width of the dental follicle ranged from 0.0 to 4.0 mm, the distal face being the one most frequently involved, and stage 7 of root formation showing the highest incidence. An inactive enamel reduced epithelium and inactive epithelium remnant also showed a high incidence. Dense connective tissue showed a high incidence, chronic inflammation was infrequent and calcification was a common finding. There was a significant association between the progression of the rhizogenesis and the transformation of the enamel reduced epithelium into a stratified squamous epithelium. No significant association was found between rhizogenesis and the other morphological findings or between the latter and the width of the pericoronal space. It was concluded that there was no clinically significant correlation between the radiographic and morphological features. Every asymptomatic unerupted third molar should be followed up and the follicular tissue analyzed.</p> ]]></description>  
<dc:creator>David Moraes de OLIVEIRA, Emanuel S&#225;vio de Souza ANDRADE, M&#225;rcia Maria Fonseca da SILVEIRA, Igor Batista CAMARGO</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>36</prism:startingPage> 
<prism:endingPage>40</prism:endingPage> 
<pubDate>2008-2-8</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0029.htm</link> 
<title>Association Study of Aromatase Gene (CYP19A1) in Essential Hypertension</title> 
<description><![CDATA[ <p>Background: As aromatase-deficient mice, which are deficient in estrogens, reportedly have reduced blood pressure, the aromatase gene (CYP19A1) is thought to be a susceptibility gene for essential hypertension (EH). The aim of the present study was to investigate the relationship between CYP19A1 and EH by examining single nucleotide polymorphisms (SNPs).</p> <p>Methods: Five SNPs in the human CYP19A1 gene (rs1870049, rs936306, rs700518, rs10046 and rs4646) were selected, and an association study was performed in 218 Japanese EH patients and 225 age-matched normotensive (NT) individuals.</p> <p>Results: There were significant differences between these groups in the distribution of genotypes rs700518 and rs10046 in male subjects, and genotypes rs700518, rs10046 and rs4646 in female subjects. On multiple logistic regression analysis, a significant association between rs700518 (p=0.023) and rs10046 (p=0.036) in male subjects and rs700518 in female subjects (p=0.018) was noted. Interestingly, the risk genotypes of rs700518 and rs10046 showed a sex-dependent inverse relationship. Both SBP and DBP levels were higher in total (cases and controls) male subjects with the G/G genotype with rs700518 or the T/T genotype with rs10046 than in male subjects without the G/G genotype or T/T genotype. SBP levels were lower in female subjects with the G/G genotype with rs700518 than in female subjects without G/G. The A-T haplotype constructed with rs1870049 and rs10046 was a susceptibility marker for EH.</p> <p>Conclusions: We confirmed that rs700518 and rs10046, as well as a haplotype constructed with rs1870049 and rs10046, in the human CYP19A1 gene can be used as genetic markers for gender-specific EH.</p> ]]></description>  
<dc:creator>Masanori Shimodaira, Tomohiro Nakayama, Naoyuki Sato, Kosuke Saito, Akihiko Morita, Ichiro Sato, Teruyuki Takahashi, Masayoshi Soma, Yoichi Izumi</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>29</prism:startingPage> 
<prism:endingPage>35</prism:endingPage> 
<pubDate>2008-2-7</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0024.htm</link> 
<title>Physical Exercise and Quality of Life in Breast Cancer Survivors</title> 
<description><![CDATA[ <p>An important goal for cancer patients is to improve the quality of life (QOL) by maximising functions affected by the disease and its therapy. Preliminary research suggests that exercise may be an effective intervention for enhancing QOL in cancer survivors. Research has provided preliminary evidence for the safety, feasibility, and efficacy of exercise training in breast cancer survivors. The aim of this study was to assess the association between physical exercise and quality of life in a population of female breast cancer survivors, followed up from diagnosis to the off-treatment time period, and investigated about their exercise habits in pre-diagnosis.</p> <p>A total of 212 female breast cancer survivors consecutively registered from January 2002 to December 2006 at a Supportive Care Unit in an Italian Oncology Department were enrolled. Exercise behaviour was assessed by the Leisure Score Index (LSI) of the Godin Leisure-Time Exercise Questionnaire. Patients were asked to report their average weekly exercise for three cancer-related time periods, i.e. pre-diagnosis, during active treatment and off-treatment. Quality of life was assessed by the Italian version of the WHOQOL-BREF standardised instrument.</p> <p>Statistical analysis indicated significant differences across the cancer-relevant time-periods for all exercise behaviour outcomes: the exercise behaviour was significantly lower during both on- and off- treatment than during prediagnosis; exercise during active treatment was significantly lower than during off-treatment. QOL strongly decreases during active treatment. Significant correlations were found between total exercise on- and off-treatment and all QOL indicators. Strenuous exercise is strongly correlated with QOL. Absent/mild exercise seems to be inversely correlated with a positive perception of disease severity and with quality of life on all axes.</p> <p>Need clearly results for inclusion of physical activity programs in comprehensive, complementary treatment regimes for breast cancer patients in Italian oncology departments.</p> ]]></description>  
<dc:creator>Marco VALENTI, Giampiero PORZIO, Federica AIELLI, Lucilla VERNA, Katia CANNITA, Renato MANNO, Francesco MASEDU, Paolo MARCHETTI, Corrado FICORELLA</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>24</prism:startingPage> 
<prism:endingPage>28</prism:endingPage> 
<pubDate>2008-1-15</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0018.htm</link> 
<title>Plasmatic B-Type Natriuretic Peptide and C-Reactive Protein in Hyperacute Stroke as Markers of Ct-Evidence of Brain Edema</title> 
<description><![CDATA[ <p>OBJECTIVE. Plasmatic B-type-natriuretic peptide (NT-PBNP) and C-reactive protein (CRP) have been reportedly elevated in stroke patients; however their clinical significance remains uncertain. The purpose of this work is to investigate whether elevation of these proteins at baseline predicts CT-evidence of brain edema.</p> <p>METHODS. We recruited 41 consecutive patients with stroke and determined NT-PBNP and CRP at baseline (within 5 hours after onset), after 48-72 hours, and at discharge. Stroke severity was measured by means of the NIHS scale at baseline and at discharge. We also carried out brain CT at admittance and after 48 hours.</p> <p>RESULTS. There were 29 ischemic strokes and 12 hemorrhagic strokes. Evidence of brain edema on delayed scan was seen in 14 patients. Baseline levels of NT-PBNP did not predict CT-evidence of edema but CRP levels did so significantly (0.7 mg/dl in patients without edema versus 4.7 mg in patients with edema; p=0.001). Both NT-PBNP and PC levels correlated poorly to NIHSS score and increased markedly from baseline to the second determination in patients with edema. For these patients the NT-PBNP increase was 133.6 pmol/l in comparison to 1.58 pmol/l in patients without edema (p=0.002). Neither CRP nor NT-PBNP baseline levels were predictive of dependency or death.</p> <p>CONCLUSIONS. We conclude that CRP at baseline but not NT-PBNP predicts CT evidence of brain edema in stroke patients. We hypothesize that NT-PBNP levels elevated in response to edema after 48 hours of admission.</p> ]]></description>  
<dc:creator>Pedro J Modrego, Beatriz Boned, Juan J Berlanga, Mercedes Serrano</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>18</prism:startingPage> 
<prism:endingPage>23</prism:endingPage> 
<pubDate>2008-1-13</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0009.htm</link> 
<title>Does eGFR improve the diagnostic capability of S-Creatinine concentration results? A retrospective population based study</title> 
<description><![CDATA[ <p>The use of MDRD-eGFR to diagnose Chronic Kidney Disease (CKD) is based on the assumption that the algorithm will minimize the influence of age, gender and ethnicity that is observed in S-Creatinine concentration and thus allow a single cut-off at which further diagnostic and therapeutic actions should be considered. This hypothesis is tested in a retrospective analysis of outpatients (N=93,404) and hospitalised (N=35,572) patients in UK and Sweden, respectively. An algorithm based on the same model as the MDRD-eGFR algorithm was derived from simultaneously measured S-Creatinine concentrations and Iohexol GFR in a subset of 565 patients. The combined uncertainty of using this algorithm was estimated to about 15 % which is about three times that of the S-Creatinine concentration results. The diagnostic performance of S-Creatinine concentration was evaluated using the Iohexol clearance as the reference procedure. It was shown that the diagnostic capacity of MDRD-eGFR, as it stands, has no added value compared to S-Creatinine. The gender and age differences of the S-Creatinine concentrations in the dataset persist after applying the MDRD-eGFR algorithm. Thus, a general use of the MDRD-eGFR does not seem justified. Furthermore the claim that the eGFR is adjusted for body area is misleading; the algorithm does not include any body size marker. It is thus a dangerous marker for guiding drug administration.</p> ]]></description>  
<dc:creator>Anders Kallner, Peter A Ayling, Zahra Khatami</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>9</prism:startingPage> 
<prism:endingPage>17</prism:endingPage> 
<pubDate>2008-1-5</pubDate>
<category>Research Paper</category>
</item>

<item>
<link>http://www.medsci.org/v05p0001.htm</link> 
<title>Differential Constitutive and Cytokine-Modulated Expression of Human Toll-like Receptors in Primary Neutrophils, Monocytes, and Macrophages</title> 
<description><![CDATA[ <p>Human Toll-like receptors (TLRs) comprise a family of proteins that recognizes pathogen-associated molecular patterns (PAMPs) and initiates host innate immune responses. Neutrophils, monocytes, and macrophages are critical cellular components of the human innate immune system. Proinflammatory cytokines, such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), and interferon-&#947; (IFN-&#947;), have been shown to up-regulate microbicidal activity in these effector cells of innate immunity. Currently, the cellular and molecular mechanisms responsible for these effects are not completely understood. We hypothesized that these cytokines may up-regulate TLR expression as a mechanism to facilitate microbial recognition and augment the innate immune response. Using quantitative realtime rt-PCR technology, we examined constitutive expression of TLR2, TLR4, TLR5, and TLR9 mRNA and the effects of G-CSF, GM-CSF, M-CSF, and IFN-&#947; on TLR mRNA expression in purified populations of normal human neutrophils, monocytes, and monocyte-derived macrophages. Relative constitutive expression of TLR2, TLR4, and TLR9 was similar in neutrophils and monocytes. Constitutive expression of TLR5 was less in neutrophils compared to monocytes. Constitutive expression of TLR4 was greater and that of TLR9 lower in monocyte-derived macrophages compared to monocytes. Of the cytokines examined, IFN-&#947; and GM-CSF caused the greatest effects on TLR expression. IFN- &#947; up-regulated TLR2 and TLR4 in neutrophils and monocytes. GM-CSF up-regulated expression of TLR2 and TLR4 in neutrophils and TLR2 in monocytes. TLR5 was down-regulated by inflammatory cytokines in monocytes. These results suggest a potential role for IFN- &#947; and/or GM-CSF as therapeutic immunomodulators of the host defense to infection.</p> ]]></description>  
<dc:creator>D. Shane O'Mahony, Uyenvy Pham, Ramesh Iyer, Thomas R. Hawn, W. Conrad Liles</dc:creator>
<dc:source>International Journal of Medical Sciences</dc:source>
<dc:publisher>Ivyspring International Publisher</dc:publisher> 
<prism:volume>5</prism:volume> 
<prism:number>1</prism:number> 
<prism:startingPage>1</prism:startingPage> 
<prism:endingPage>8</prism:endingPage> 
<pubDate>2008-1-4</pubDate>
<category>Research Paper</category>
</item>

<atom:link href="http://www.medsci.org/rss/v5.xml" rel="self" type="application/rss+xml" />
</channel>
</rss>
